USPTO serial 79446709
DEYZOLY
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- MILLER, CHARLES FREDERICK
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with DEYZOLY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Miriam D. Trudell
Miriam D. Trudell Davis Graham & Stubbs LLP3400 Walnut Street, Suite 700Denver, CO 80205United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); medical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); pharmaceutical preparations, namely for treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia; medical preparations for the treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia | ACTIVE | — |
| 010 | Medical devices for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders, namely, short bowel syndrome (SBS) in humans by introducing pharmaceutical preparations, and parts and fittings therefor; medical devices for treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia by introducing pharmaceutical preparations, and parts and fittings therefor | ACTIVE | — |
| 044 | Medical services, namely, treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS) and pharmaceutical services, namely, treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); medical and pharmaceutical advice in the field of treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); medical services, namely, treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia and pharmaceutical services, namely, treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia; medical and pharmaceutical advice, namely in relation to treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 29, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 28, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 28, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 28, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 11, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 23, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 23, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 9, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 8, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 31, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 27, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 27, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 26, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |